Somatropin (HGH 191AA)

Somatropin is recombinant human growth hormone — the identical 191-amino-acid sequence — with a deep clinical trial record in GH deficiency and related growth disorders; the off-label community runs it primarily for performance and muscle gain, and for anti-aging and recovery. Community users most commonly report 500 mcg daily; clinician-guided protocols span 100 mcg to 6 mg/day subcutaneously. The exploratory indications list is long, but most lack posted results — the evidence base is substantially thinner off-label than the volume of interest implies.

Half-life~3 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.64.91.54.04.14.0

Research Evidence

Evidence shape

Somatropin sits at the top tier of clinical evidence: 207 registered trials across 57 independent sponsors, 13 blinded trials with posted results, and a combined enrollment above 37,000 participants, with Phase 3-grade data covering growth hormone deficiency, HIV-associated lipodystrophy, idiopathic short stature, and Turner syndrome. Fifteen of 96 mapped indications have results; the other 81 are thin or single-trial entries, most without posted results. Obesity, cognitive function in aging, and NAFLD each have exploratory trials on record but none with results.

Depthhow much
206 registered trials
136 completed · 44 with posted results · 24 recruiting / active · combined n=38076
Breadthhow many areas
94 indications mapped
14 with results · 69 thin / exploratory · 1 animal-only · 54 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
11 blinded with results · 60 distinct sponsors · AE rows aggregated from 36 trials · 56 linked publications on registered trials
Breadth and depth212 rows captured
Human
direct clinical signal
211
Animal
translational support
1
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

Somatropin (HGH 191AA) side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Fusion X Peptides
GB
1500 mg
$268.45
$0.174/mg
2
Valhalla Biolabs
--
100 mg
$69.99
$0.7/mg
3
peptidesourcehub.com
CN
50 mg
$74.90
$1.5/mg
4
High Purity Peptides
Hong Kong
10 mg×10
$30.00
$3/mg
5
montrealpeptides.ca
CA
10 mg
$55.00
$5.5/mg
6
dutchlabs.eu
--
10 mg
$65.15
$6.52/mg

price offers can be sorted by column · 3 out-of-stock offers not shown

1-6 of 11

Somatropin (HGH 191AA) dosing & protocol

How Somatropin (HGH 191AA) is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 141
Typical dose
2.5 mg240 µg – 10 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 23 reported doses · darker = more
Frequency
daily
Route
subQ

Across 141 trial participants, subcutaneous doses spanned a wide range — from around 240 mcg to 10 mg — with weight-based regimens the norm rather than a fixed milligram figure; the most commonly recorded protocols ran approximately 0.025–0.175 mg/kg daily, though at least one trial used a weekly dosing schedule.

141 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Starting dose
100 µg100 µg – 6 mg
start
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 3 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

Clinicians typically prescribe 6 mg of somatropin subcutaneously each day, though reported doses span from 0.1 mg to 6 mg daily, and no specific cycling regimen is documented for this tier.

1 source
Anecdotal
Community-reported real-world use · n = 1
Typical dose
500 µg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
across 1 dosed source · darker = more agree
Frequency
unspecified
Route
subQ

Based on a single community report, the dose is 500 mcg administered subcutaneously, while the frequency of administration and any cycling regimen were not specified.

1 source

Regulatory safety notes

Warnings and precautions
  • • Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk •
  • • Prader-Willi Syndrome in Children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment Discontinue treatment if these signs occur •
  • • Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin in particular meningiomas in patients treated with radiation to the head for their firs…
  • • Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment •
  • • Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction •
  • • Hypersensitivity: Serious hypersensitivity reactions may occur. In the event of an allergic reaction, seek prompt medical attention • Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome – especially in adults) : May occur frequently. Reduce dose…
  • • Hypoadrenalism: Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism •
  • • Hypothyroidism: May first become evident or worsen. Monitor thyroid function periodically •
Contraindications
  • • • Acute Critical Illness • Children with Prader-Willi syndrome who are severely obese or have severe respiratory impairment – reports of sudden death • Active Malignancy • Hypersensitivity to somatropin or excipients •…
  • • patients with: • Acute Critical Illness Treatment with pharmacologic amounts of somatropin is contraindicated in
  • • patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure [see Warnings and Precautions (5.1) ]. • P…
  • • patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was u…
  • • patients with any evidence of progression or recurrence of an underlying intracranial tumor. • Hypersensitivity GENOTROPIN is contraindicated in
  • • patients with a known hypersensitivity to somatropin or any of its excipients. The 5 mg and 12 mg presentations of GENOTROPIN lyophilized powder contain m-cresol as a preservative. Systemic hypersensitivity reactions ha…
  • • patients with active proliferative or severe non-proliferative diabetic retinopathy. • Closed Epiphyses Somatropin should not be used for growth promotion in pediatric
  • • patients with closed epiphyses.
Drug interactions
  • • Inhibition of 11ß-Hydroxysteroid Dehydrogenase Type 1: May require the initiation of glucocorticoid replacement therapy. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance dose…
  • • Replacement: Should be carefully adjusted (7.2) • Cytochrome P450-Metabolized
  • • Drugs: Monitor carefully if used with somatropin (7.3) •
  • • Estrogen: Larger doses of somatropin may be required in women (7.4) •
  • • Agents: May require adjustment (7.5)

Related peptides

CJC-1295IpamorelinMK-677HexarelinGHRP-6GHRP-2SermorelinIpamorelin / CJC-1295 BlendCapromorelin